Introduction. Although endometriosis is a benign disease, it shares some features with cancers, such as invasiveness and the potential to metastasize. This study sought to investigate the epithelial-mesenchymal transition status in human endometriotic lesions. Material and methods. Thirteen endometriosis patients and 10 control women without endometriosis undergoing surgery for benign indications were recruited. We examined the expression of E-cadherin, vimentin, and epithelial-mesenchymal transition-induced transcriptional factors, such as Snail and ZEB1, by immunohistochemistry. We evaluated the expression of each marker in epithelial cells of both endometriotic lesions (ovarian endometrioma, deep infiltrating endometriosis, adenomyosis) and normal endometria. The correlation between ZEB1 expression and serum level of CA125 was also investigated. Results. Immunohistochemical analysis revealed that although E-cadherin, vimentin, and Snail were expressed in epithelia of normal endometria and endometriotic lesions, ZEB1 expression was only expressed in epithelia of endometriotic lesions. Additionally, ZEB1 was most frequently observed in epithelial cells of invasive endometriosis. The endometriosis patients with high serum CA125 level were more likely to have ZEB1-positive lesions. Conclusions. This is the first observation of ZEB1 expression in epithelial cells of benign disease. The preferential expression of ZEB1 in epithelial cells of endometriotic lesions suggests that these cells may have, at least in part, a higher level of mesenchymal features possibly via ZEB1-driven epithelial-mesenchymal transition than normal endometria and that ZEB1 can be a potential indicator of invasiveness or severity of endometriosis.
Introduction
Endometriosis is a common disease that affects approximately 10% of reproductive-age women. This condition, which frequently manifests as pelvic pain and infertility, is characterized by the presence of ectopic endometrial tissues composed of epithelial and stromal cells outside the uterine cavity. Although several hypotheses regarding the pathogenesis of endometriosis exist, its pathophysiology remains poorly understood.
Although endometriosis is a benign, estrogen-dependent disease, endometriotic cells share some features with cancer cells, such as invasiveness and the potential to metastasize (1) . Therefore, the establishment and development of endometriosis is thought to share several mechanisms, including epithelial-mesenchymal transition (EMT), with malignant disorders (2, 3) . In particular, there is emerging evidence that EMT is involved in the pathogenesis of endometriosis (4, 5) .
EMT occurs in cancer progression as well as during organogenesis and wound healing (6) . EMT is characterized by the loss of epithelial features and expression of mesenchymal features, concurrent with increased migration and invasion abilities. Indeed, loss of E-cadherin correlates closely with cancer invasion, leading to a poor prognosis in patients with endometrial carcinoma (7) . Transforming growth factor-b (TGF-b) plays a crucial role in EMT during development, and TGF-b expression by tumors and surrounding stroma also drives EMT in cancer (8) . TGF-b represses expression of epithelial genes and induces expression of mesenchymal genes (9) . Some previous studies have reported the expression of TGF-b in normal endometria and endometriotic tissues (10) , suggesting a relation between endometriosis and EMT.
Several E-cadherin transcriptional repressors have been identified, such as Snail, Slug, and Twist (11). ZEB1 is a transcription factor implicated in tumor cell EMT (12, 13) . Originally identified as a DNA-binding protein (14) , ZEB1 contains a homeodomain and two zinc finger clusters, and downregulates gene expression by binding to a subset of E-boxes and functioning as a transcriptional repressor (15) . ZEB family members have also been identified as downstream effectors of the TGF-b signaling pathway (9) . ZEB1 regulates E-cadherin expression by binding to two high-affinity binding sites in the E-cadherin promoter region (13) .
As observed in cancer metastasis, endometriosis-initiating cells possess a mesenchymal capacity to migrate following their attachment to remote areas. We focused on this observation and hypothesized that EMT of endometriotic epithelial cells induces the establishment and development of endometriosis. The aim of this study is to investigate the expression of EMT-related markers in epithelial cells of both normal endometria and endometriotic lesions to find a marker specific for endometriosis.
Material and methods

Sample collection
In this study, we recruited 13 women aged 24-42 years (33.7 AE 1.5, mean AE SE) who underwent their first surgery for endometriosis or adenomyosis at our hospital. We examined 17 sample blocks, including ovarian endometriomas (n = 6), adenomyosis (n = 6), and deep infiltrating endometriosis of the sacrouterine ligament (n = 5). Four of 13 patients had both ovarian endometrioma and deep infiltrating endometriosis (Table 1) . A histologic diagnosis of endometriosis was made according to the presence of ectopic endometrial gland-like structures with endometrial stroma. Cases lacking gland structures were excluded from analysis in this study. Normal endometrial samples (proliferative phase: n = 5, secretory phase: n = 5) from 10 women aged 42-49 years (45.8 AE 1.5, mean AE SE) who underwent hysterectomy for benign indications without endometriosis were included for comparison. For each patient, data were collected regarding age at surgery, menstrual cycle phase, type of endometriosis, and serum CA125 level between periods before surgery. None of these patients received hormonal therapy before surgery.
Immunohistochemistry
Tissue samples were embedded in paraffin following fixation with 10% formalin, and paraffin sections were cut to a thickness of 3 lm. Tissue sections were deparaffinized and rehydrated. Histological analysis was performed by hematoxylin and eosin staining. For immunohistochemistry, antigen retrieval was accomplished by microwave treatment in a citrate buffer. After the inhibition of endogenous peroxidase activity by 3% H 2 O 2 and blocking with 3% bovine serum albumin, sections were incubated with the following primary antibodies: anti-ZEB1 (goat polyclonal antibody, 1:200; Santa Cruz Biotechnology; Santa Cruz, CA, USA), anti-E-cadherin (clone NCH-38, 1:200; Dako; Glostrup, Denmark), anti-vimentin (clone V9, 1:200; Dako), and anti-Snail (rabbit polyclonal antibody, 1:100; Abcam; Cambridge, UK). Sections were then washed with phosphate-buffered saline (PBS) and incubated with ABC reagent mix (Vector Laboratories; Burlingame, CA, USA), followed by staining with 3,3 0 -diaminobenzidine (DAB, Vector Laboratories) and counterstaining with hematoxylin. Appropriate positive and
Key Message
ZEB1 is expressed in epithelial cells only in endometriotic lesions, not normal endometria, which may reflect epithelial-mesenchymal transition (EMT) of endometriotic epithelia. Additionally, ZEB1 was most frequently observed in epithelial cells of invasive endometriosis.
negative controls confirmed the specificity of each antibody.
Statistical analyses
Data were analyzed using GraphPad PRISM software version 6.03 (GraphPad Software, Inc., San Diego, CA, USA). Fisher's exact test was used for detection of significant differences in ZEB1 staining between normal endometria and ectopic lesions. The Mann-Whitney test was performed to determine significant differences in serum CA125 levels between ZEB1-positive and ZEB1-negative endometriosis tissues. Data are presented as medians and ranges. Results were considered statistically significant when p < 0.05.
Ethical approval
Written informed consent was obtained from each patient, and ethical approval was obtained from the ethical commission of the Keio University School of Medicine (reference approval number 20120090, date of approval 25 June 2013).
Results
Mesenchymal features of epithelia of normal endometria and endometriotic lesions
Several studies have shown differences between normal endometria of women without endometriosis (normal endometria), eutopic endometria, and endometriotic lesions (ectopic endometria) of women with endometriosis (16) . In this study, to identify differences in mesenchymal features of epithelial cells between normal endometria and endometriotic lesions, we first performed immunohistochemistry using vimentin (a mesenchymal maker), Snail (an EMT maker), and E-cadherin (an epithelial maker).
E-cadherin was expressed only in epithelia of all samples, including both normal endometria and endometriotic lesions, as expected (Figure 1a,b) . However, some epithelia displayed differential intensities in E-cadherin staining, giving an isolated/scattered pattern appearance (Figure 1c) , mainly in adenomyosis and deep infiltrating endometriosis (Table 2 ), which may indicate that E-cadherin-negative cells in the epithelia lose epithelial features via EMT.
In contrast, although hematoxylin and eosin staining of all epithelia demonstrated epithelial morphology, these tissues also exhibited mesenchymal characteristics, such as expression of vimentin and Snail. Vimentin and Snail expression was also observed in all epithelia as well as stroma of both normal endometria and endometriotic lesions (Figure 1d-g ). In normal endometria, vimentin and Snail were expressed in both luminal and glandular epithelia (Figure 1a,d,f) . No differences in E-cadherin, vimentin and Snail expression were observed on normal endometria between proliferative and secretory phases (data not presented).
ZEB1 expression
ZEB1 is a transcription factor that inhibits E-cadherin expression and has been implicated in malignant progression of epithelial tumors (17) . Therefore, we next examined ZEB1 expression in the epithelia of normal endometria and endometriotic lesions. Immunostaining revealed ZEB1 expression in epithelia of each type of endometriosis (Figure 2 ), including adenomyosis (Table 3 ). Interestingly, in two patients, ZEB1 epithelia staining was negative in ovarian endometrioma, but positive in deep infiltrating endometriosis within the same individual (Table 2 ). In contrast, although stroma cells of normal endometria exhibited ZEB1 expression, no staining was observed in luminal or glandular epithelial cells of normal endometria (Figure 2a,b) . A significant difference in ZEB1 expression was observed between normal endometria and endometriotic lesions (Fisher's exact test, p = 0.0039) (Figure 2c ). To investigate the correlation between ZEB1 expression and endometriosis progression, we reviewed the patients' clinical information. As the scoring of the revised American Society for Reproductive Medicine (rASRM) does not include adenomyosis, we extracted data regarding serum CA125 levels prior to surgery. Although no significant difference was observed, patients with ZEB1-positive lesions were more likely to have higher levels of serum CA125 (Figure 2d ). These data may suggest that ZEB1 expression can be a potential indicator of endometriotic invasiveness or severity.
Discussion
In this study, we demonstrated that ZEB1 was highly expressed in the epithelial cells of endometriosis lesion. As the epithelia of normal endometrium did not express ZEB1, epithelial ZEB1 expression appears to be characteristic of endometriosis. Although ZEB1 expression has been reported in a variety of cancer cells, to our knowledge this is the first report of ZEB1 expression in epithelial cells associated with a benign disease.
In normal endometrium, epithelial cells express both E-cadherin and vimentin. Endometrium may be likely to undergo EMT, because endometrium rapidly recovers from menstruation, a kind of tissue damage, each month. As EMT occurs as a physiological response to tissue damage or injury, the mesenchymal characteristics of endometrium may facilitate this recovery. In the repair of tubules following kidney injury, mesenchymal cells must ultimately transition into epithelial cells (18) . Expression of BMP-7, which abrogates TGF-b-induced epithelial to mesenchymal transition, was reported to reverse chronic renal injury (19) . Since TGF-b expression in endometrium is upregulated during menstruation (10), the same pathway may function in menstrual regeneration. ZEB1 is a transcription factor implicated in EMT. The key role of ZEB1 in EMT is repression of E-cadherin expression and inhibition of microRNAs required for epithelialization (20, 21) . ZEB1 expression confers mesenchymal cellular characteristics, such as motility and anoikis resistance (22, 23) . The loss of cell polarity and the promotion of migration by EMT facilitate the invasion and metastasis of epithelial malignancies. Several reports have linked ZEB1 expression with progression of malignancy (17) . High ZEB1 expression levels are correlated with the loss of E-cadherin expression as well as increased migratory and invasive potential of endometrial cancer cells (24, 25) . Despite being benign, endometriotic lesions have an invasive, cancer-like appearance, implying high motility, which contributes to the establishment of all types of endometriosis. ZEB1 expression in endometriotic lesions may provoke these cancer-like characteristics to advance endometriosis. Indeed, in our analysis, endometriosis phenotypes with more invasive appearances, such as adenomyosis and deep infiltrating endometriosis, more frequently expressed ZEB1 compared with ovarian endometriomas. Furthermore, two patients harbored ZEB1-positive epithelia in their deep infiltrating endometriosis lesions and ZEB1-negative epithelia in their ovarian endometriomas (Table 2) . Therefore, we speculate that ZEB1 expression can be an indicator of migratory and invasive potential even in endometriosis, a benign disease.
In this context, we previously reported that some endometrial cells had a unique invasiveness property (26) , and an endometrial side population of cells, which is thought to be a stem cell population, was also strongly invasive (27) . As migration and invasion are definitely required for the establishment of endometriosis, we have hypothesized that endometriotic lesions can be derived from endometrial stem cells (28, 29) . The results of this study may indicate that ZEB1-expressing endometrial stem cells initiate endometriotic lesions. Indeed, in cancer stem cells, EMT-inducing transcription factors including Snail and ZEB1 are associated with maintenance of stemness (30) . It is striking that ZEB1 promotes stemness of cancer cells by inhibiting microRNAs (21) , further supporting the present speculation.
MicroRNA studies have been increasing in endometriosis research (31) . Recent cancer studies indicated that miRNAs could regulate cancer invasion and metastasis via EMT (32) . In 2008, four reports, published almost simultaneously, suggested that the miR-200 family members played the significant role in keeping the epithelial phenotype by targeting ZEB1 (20, (33) (34) (35) . More recently, non-cancer study using human epithelial-like endometriotic cell line (12Z) revealed that miR-200b overexpression could downregulate ZEB1 and ZEB2 expression, decrease invasiveness and motility, and increase E-cadherin expression and side population rate (36) . These findings also support our speculations that ZEB1 could confer invasiveness and stemness on endometriotic epithelial cells.
The reported expression of E-cadherin has been inconsistent. Some studies showed no significant difference in E-cadherin expression on epithelia between normal endometria and endometriotic lesions (4, (37) (38) (39) , in agreement with our data. Other studies demonstrated that Ecadherin expression was higher in normal endometrial epithelia than in endometriotic epithelia (40) (41) (42) (43) (44) (45) (46) . Interestingly, Matsuzaki et al. (5) reported that epithelia of deep infiltrating endometriosis and black peritoneal lesions showed higher E-cadherin expression compared with that of ovarian endometriosis, red peritoneal lesions, and menstrual endometria. Furthermore, Gaetje et al. and Bartley et al. mentioned E-cadherin-negative epithelial cells in endometriotic lesions (2, 4) , which is consistent with the isolated/scattered pattern of our E-cadherin staining data, and these E-cadherin-negative epithelial cells possessed higher invasive ability (2) . Further investigation of the relation between ZEB1 and E-cadherin in each type of endometriotic lesion is required to resolve the inconsistency.
ZEB1 is expressed only in the epithelia of endometriotic lesions, not of endometria. Although it has been reported that Snail expression on epithelia was higher in endometriotic lesions than endometria (4,45), we could not identify the differential expression of Snail, perhaps because of the small numbers of samples. However, in varying degrees, Snail is expressed in both normal endometria and endometriotic lesions.
The sample size of this study is relatively limited at the moment. The number of the samples should be increased next to consolidate the correlation between serum CA125 level, severity of endometriosis and ZEB1 expression. In addition, while ZEB1 is expressed only on the epithelia of endometriotic lesions, Snail is expressed on the epithelia of both normal endometria and endometriotic lesions. The differential expression of ZEB1 and Snail on normal endometria should be addressed, and may further clarify the invasive properties of endometriosis.
In conclusion, we have reported for the first time that ZEB1 is expressed only in epithelial cells in endometriotic lesions, not normal endometria, which may reflect the prospect that ZEB1 plays an important role in EMT endometriosis pathogenesis. The characteristic pattern of ZEB1 expression suggests that endometriotic epithelia have a higher level of mesenchymal features via EMT than normal endometrial epithelia and that ZEB1 can be a potential indicator of invasiveness or severity.
